162. 類天疱瘡（後天性表皮水疱症を含む。） Pemphigoid Clinical trials / Disease details
臨床試験数 : 83 / 薬物数 : 128 - (DrugBank : 51) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03099538 (ClinicalTrials.gov) | August 15, 2017 | 21/3/2017 | Ixekizumab in the Treatment of Bullous Pemphigoid | Ixekizumab in the Treatment of Bullous Pemphigoid | Bullous Pemphigoid;Pemphigoid | Drug: Ixekizumab | Mayo Clinic | Eli Lilly and Company | Completed | 18 Years | N/A | All | 4 | Phase 2 | United States |